

March 18, 2014

## **Mrs Pascale Augé appointed as Chief Executive Officer, Inserm Transfert**

---

On the initiative of the Chairman and CEO of Inserm, Prof. André Syrota, the Supervisory Board of Inserm Transfert has appointed:

- Mrs Pascale Augé as Chief Executive Officer of Inserm Transfert.

Mrs Pascale Augé was previously Head of Technology Transfer and Entrepreneurship at Institut Pasteur; she succeeds Mrs Cécile Tharaud, following the appointment of the latter as President and Managing Partner of Inserm Transfert Initiative.

On January 1st 2006, Inserm entrusted all its technology and knowledge transfer activities to Inserm Transfert under a public service delegation agreement. Inserm Transfert's total revenues reached €11.5m in 2013, with a 63% growth over the past three years.

Inserm Transfert, as a shareholder, has a seat on the Supervisory Board of Inserm Transfert Initiative, and will be represented by its CEO.

Inserm Transfert Initiative becomes a permanent guest on the Supervisory Board of Inserm Transfert, and will be represented by its President.

These decisions, effective April 1<sup>st</sup> 2014, consolidate the organisation of Inserm's technology transfer activities and pre-seed and seed financing of young biotechnology start-ups.

### **Pr. André Syrota, Chairman and CEO of Inserm, and non executive Chair of the Supervisory Board of Inserm Transfert:**

*"Inserm has become Europe's leading biomedical research organisation in just a few years. By reinforcing these two companies dedicated to technology-transfer and entrepreneurship in order to serve both our researchers and health industries, Inserm Transfert and Inserm Transfert Initiative are now more than ever in a position to strengthen their leadership position within the ecosystems for innovation in life sciences.*

*Our strategic options have proven they work: Inserm Transfert has been generating profits since 2011, and the French Court of Auditors has applauded its business model."*

### **Pascale Augé, CEO of Inserm Transfert**

*"2013 was an important year for Inserm Transfert: the company generated profits in excess of €1m for the second year running. Its profits moreover grew by more than 10%; they get reinvested every year into proof of concept projects. This performance is driven in particular by the European presence of Inserm Transfert and its pioneering strategy for large-scale industrial partnerships.*

*This technology-transfer organisation has earned respect worldwide for its skills, top-tier teams and expertise. Amid the fierce international competition to bring academic research to market, I intend to push ahead our efforts with and strengthen the close relationships we have built with health industrial players, while deepening synergistic, trust-based cooperation ties with all partners in the technology-transfer ecosystem in France, in order to nurture innovation and entrepreneurial drive.*

*We are looking for new growth opportunities to take Inserm Transfert to the next level of maturity and development.”*

**Cécile Tharaud, Inserm Transfert Initiative CEO:**

*“After working with Inserm Transfert’s teams to build this organisation that is now recognised as the leading technology transfer office within the health sector in France, I am delighted to hand over to Mrs Pascale Augé.*

*It is now time for me to lead Inserm Transfert Initiative into a new stage in its development. As a team, we will boost its entrepreneurial dynamic and international network.*

*Teamwork between Inserm Transfert and Inserm Transfert Initiative is essential to the performance of this ecosystem: their corporate bodies have accordingly organised the governance of each company so that they get represented on the Supervisory Board of one another.*

*I would like to take this opportunity to acknowledge each and every employee of Inserm Transfert for their team performance, dedication and innovative drive, and for the trust they placed in their executive board and myself.”*

Pascale Augé

Before joining Inserm Transfert, Pascale had led Institut Pasteur’s Technology Transfer and Entrepreneurship office since 2011. She has more than 15 years’ experience in the fields of technological innovation in life science and health technology, research transfer and entrepreneurship, and the biotechnology start-up industry. She headed business development at Neurotech, Entomed and AB Science then operational strategy in the sciences and health technology, and ran Ernst & Young activities in France. She also chaired the evaluation committee reviewing “high-market-potential products, technologies or services” at France’s Agence Nationale de la Recherche from 2008 to 2011.

Pascale Augé holds a doctorate in molecular pharmacology, experimental pharmacology and metabolism from Université Paris V, and a chemical engineering degree from the École de Chimie de Strasbourg.

<b>Press Contact</b>	
Inserm Priscille Rivière 0033 1 44 23 60 97 presse@inserm.fr	Inserm Transfert Céline Cortot 0033 1 55 03 01 26 communication@inserm-transfert.fr